{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:33:30Z","timestamp":1787758410549,"version":"build-2784847793"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Subacute sclerosing panencephalitis (SSPE) is a neurodegenerative disorder because of the persistence of mutated measles virus in the central nervous system. Till date, no curative therapy has been established for SSPE. Multiple drugs have been tried to modify the disease process but have shown mild to moderate benefit at best. It is also challenging to attribute the relative success of some strategies described in single case reports because of the known phenomenon of spontaneous improvement in 5% of patients with SSPE. Critical gaps in understanding the pathophysiological processes involved exist. Current therapies such as interferon alfa require invasive strategies for administration by the intraventricular or intrathecal route, with varying dosage regimens. Oral therapies such as isoprinosine and ribavirin are expensive and not readily available in resource-constrained settings. Most of the evidence so far favors the use of combinational regimens. In this viewpoint, we critically summarize the current evidence on disease-modifying strategies in the context of our region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_655_22","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T03:48:58Z","timestamp":1668829738000},"page":"3-9","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Disease-Modifying Therapy in Subacute Sclerosing Panencephalitis"],"prefix":"10.4103","volume":"26","author":[{"given":"Divyani","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvasini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240828","first-page":"7","article-title":"Cellular inclusions in cerebral lesions of lethargic encephalitis","volume":"9","author":"Dawson","year":"1933","journal-title":"Am J Pathol"},{"key":"R2-2-20240828","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/221974a0","article-title":"Subacute sclerosing panencephalitis: Isolation of measles virus from a brain biopsy","volume":"221","author":"Horta-Barbosa","year":"1969","journal-title":"Nature"},{"key":"R3-2-20240828","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM196909112811103","article-title":"Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis","volume":"281","author":"Payne","year":"1969","journal-title":"N Engl J Med"},{"key":"R4-2-20240828","first-page":"e2058","article-title":"Subacute sclerosing panencephalitis","volume":"29","author":"Garg","year":"2019","journal-title":"Rev MedVirol"},{"key":"R5-2-20240828","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.braindev.2006.01.008","article-title":"Long term survival in subacute sclerosing panencephalitis: An enigma","volume":"28","author":"Prashanth","year":"2006","journal-title":"Brain Dev"},{"key":"R6-2-20240828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0387-7604(83)80006-0","article-title":"Cell mediated immunity and effects of \u201cthymic humoral factor\u201d in 15 patients with SSPE","volume":"5","author":"Handzel","year":"1983","journal-title":"Brain Dev"},{"key":"R7-2-20240828","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1749-6632.1988.tb27199.x","article-title":"Impaired measles-specific cytotoxic T-cell response in subacute sclerosing panencephalitis","volume":"540","author":"Dhib-Jalbut","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"R8-2-20240828","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1073\/pnas.0502323102","article-title":"Laser-capture microdissection of plasma cells from subacute sclerosing panencephalitis brain reveals intrathecal disease-relevant antibodies","volume":"102","author":"Burgoon","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-2-20240828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.1983.tb04545.x","article-title":"Lymphocyte subpopulations in blood and cerebrospinal fluid from patients with subacute sclerosing panencephalitis","volume":"67","author":"Marrosu","year":"1983","journal-title":"Acta NeurolScand"},{"key":"R10-2-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejpn.2006.10.005","article-title":"Rituximab in subacute sclerosing panencephalitis","volume":"11","author":"Titomanlio","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"key":"R11-2-20240828","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM197111042851922","article-title":"Immunologic abnormalities in subacute sclerosing panencephalitis","volume":"285","author":"Moulias","year":"1971","journal-title":"N Engl J Med"},{"key":"R12-2-20240828","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0387-7604(89)80058-0","article-title":"The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine","volume":"11","author":"Gadoth","year":"1989","journal-title":"Brain Dev"},{"key":"R13-2-20240828","first-page":"309","article-title":"Letter: Interferon in serum and cerebrospinal fluid in subacute sclerosing panencephalitis","volume":"115","author":"Joncas","year":"1976","journal-title":"Can Med Assoc J"},{"key":"R14-2-20240828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0883073819860631","article-title":"Role of the Th1 and Th17 pathway in subacute sclerosing panencephalitis","volume":"34","author":"Uygun","year":"2019","journal-title":"J Child Neurol"},{"key":"R15-2-20240828","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/088307389901400702","article-title":"Lymphocyte subsets and inflammatory mediators in patients with subacute sclerosing panencephalitis","volume":"14","author":"Tekg\u00fcl","year":"1999","journal-title":"J Child Neurol"},{"key":"R16-2-20240828","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.braindev.2014.09.006","article-title":"Prognosis and demographic characteristics of SSPE patients in Istanbul, Turkey","volume":"37","author":"Guler","year":"2015","journal-title":"Brain Dev"},{"key":"R17-2-20240828","first-page":"1059","article-title":"Measles sclerosing subacute panencephalitis (SSPE), an intriguing and ever-present disease: Data, assumptions and new perspectives","volume":"177","author":"Lebon","year":"2021","journal-title":"RevNeurol"},{"key":"R18-2-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gene.2018.07.062","article-title":"IL28B, IL29 and micro-RNA 548 in subacute sclerosing panencephalitis as a rare disease","volume":"678","author":"CakmakGenc","year":"2018","journal-title":"Gene"},{"key":"R19-2-20240828","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s13365-016-0442-7","article-title":"Interleukin-12 (-1188) A\/C and interferon-\u03b3 (+874) A\/T gene polymorphisms in subacute sclerosing panencephalitis patients","volume":"22","author":"Dundar","year":"2016","journal-title":"J Neurovirol"},{"key":"R20-2-20240828","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0033-1338134","article-title":"PD-1 gene polymorphism in children with subacute sclerosing panencephalitis","volume":"44","author":"Piskin","year":"2013","journal-title":"Neuropediatrics"},{"key":"R21-2-20240828","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1469-8749.1985.tb03766.x","article-title":"Use of interferon in the management of patients with subacute sclerosing panencephalitis","volume":"27","author":"Bye","year":"1985","journal-title":"Dev Med Child Neurol"},{"key":"R22-2-20240828","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.410190317","article-title":"Intrathecal interferon in subacute sclerosing panencephalitis","volume":"19","author":"Huttenlocher","year":"1986","journal-title":"Ann Neurol"},{"key":"R23-2-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0404.1988.tb03639.x","article-title":"Intrathecal interferon in subacute sclerosing panencephalitis","volume":"78","author":"Maimone","year":"1988","journal-title":"Acta NeurolScand"},{"key":"R24-2-20240828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.36.4.562","article-title":"Subacute sclerosing panencephalitis: Remission after treatment with intraventricular interferon","volume":"36","author":"Panitch","year":"1986","journal-title":"Neurology"},{"key":"R25-2-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/088307388900400103","article-title":"Intraventricular interferon treatment for subacute sclerosing panencephalitis","volume":"4","author":"Steiner","year":"1989","journal-title":"J Child Neurol"},{"key":"R26-2-20240828","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0387-7604(89)80012-9","article-title":"The effect of intraventricular interferon on subacute sclerosing panencephalitis","volume":"11","author":"Kuroki","year":"1989","journal-title":"Brain Dev"},{"key":"R27-2-20240828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1651-2227.1985.tb10973.x","article-title":"Intrathecal administration of human leukocyte interferon to a patient with subacute sclerosing panencephalitis","volume":"74","author":"Nakagawa","year":"1985","journal-title":"Acta Paediatrica"},{"key":"R28-2-20240828","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.48.2.526","article-title":"Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon","volume":"48","author":"Anlar","year":"1997","journal-title":"Neurology"},{"key":"R29-2-20240828","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.braindev.2004.07.003","article-title":"Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha","volume":"27","author":"Miyazaki","year":"2005","journal-title":"Brain Dev"},{"key":"R30-2-20240828","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/INF.0b013e31812e01e8","article-title":"Continuous intrathecal interferon alpha application in subacute sclerosing panencephalitis","volume":"26","author":"Thurner","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R31-2-20240828","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/01.WNL.0000130516.54312.A1","article-title":"Improvement of SSPE by intrathecal infusion of -IFN","volume":"63","author":"Kurata","year":"2004","journal-title":"Neurology"},{"key":"R32-2-20240828","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/WNL.64.2.402","article-title":"Improvement of SSPE by intrathecal infusion of -IFN","volume":"64","author":"Wirguin","year":"2005","journal-title":"Neurology"},{"key":"R33-2-20240828","first-page":"20","article-title":"Intravenous with intrathecal interferon in subacute sclerosing panencephalitis","volume":"43","author":"Nair","year":"1995","journal-title":"Neurol India"},{"key":"R34-2-20240828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-510X(98)00302-5","article-title":"Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis","volume":"162","author":"Gokcil","year":"1999","journal-title":"J Neurol Sci"},{"key":"R35-2-20240828","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1212\/WNL.50.1.315","article-title":"Intraventricular \u03b1-interferon in subacute sclerosing panencephalitis","volume":"50","author":"Cianchetti","year":"1998","journal-title":"Neurology"},{"key":"R36-2-20240828","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0387-7604(93)90120-W","article-title":"Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis","volume":"15","author":"Gascon","year":"1993","journal-title":"Brain Dev"},{"key":"R37-2-20240828","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ana.410290118","article-title":"Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha","volume":"29","author":"Miyazaki","year":"1991","journal-title":"Ann Neurol"},{"key":"R38-2-20240828","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/088307389801301106","article-title":"Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis","volume":"13","author":"Anlar","year":"1998","journal-title":"J Child Neurol"},{"key":"R39-2-20240828","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.clinthera.2004.11.002","article-title":"Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis","volume":"26","author":"Anlar","year":"2004","journal-title":"Clin Ther"},{"key":"R40-2-20240828","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s12325-019-00995-6","article-title":"Inosine pranobex: A key player in the game against a wide range of viral infections and non-infectious diseases","volume":"36","author":"Sliva","year":"2019","journal-title":"Adv Ther"},{"key":"R41-2-20240828","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1212\/WNL.29.6.763","article-title":"Isoprinosine in subacute sclerosing panencephalitis","volume":"29","author":"Huttenlocher","year":"1979","journal-title":"Neurology"},{"key":"R42-2-20240828","first-page":"44","article-title":"The effect of inosiplex in subacute sclerosing panencephalitis: A clinical and laboratory study","volume":"34","author":"Anlar","year":"1994","journal-title":"EurNeurol"},{"key":"R43-2-20240828","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archneur.1979.00500420084012","article-title":"Inosiplex in the treatment of subacute sclerosing panencephalitis","volume":"36","author":"Silverberg","year":"1979","journal-title":"Arch Neurol"},{"key":"R44-2-20240828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.410070216","article-title":"Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: A controlled study","volume":"7","author":"Haddad","year":"1980","journal-title":"Ann Neurol"},{"key":"R45-2-20240828","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ana.410080620","article-title":"Isoprinosine therapy and SSPE","volume":"8","author":"Huttenlocker","year":"1980","journal-title":"Ann Neurol"},{"key":"R46-2-20240828","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3476(82)80143-1","article-title":"The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis","volume":"101","author":"DuRant","year":"1982","journal-title":"J Pediatr"},{"key":"R47-2-20240828","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.410110407","article-title":"Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex","volume":"11","author":"Dyken","year":"1982","journal-title":"Ann Neurol"},{"key":"R48-2-20240828","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1212\/WNL.33.8.1053","article-title":"The effect of inosiplex on the survival of subacute sclerosing panencephalitis","volume":"33","author":"DuRant","year":"1983","journal-title":"Neurology"},{"key":"R49-2-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0387-7604(87)80044-X","article-title":"Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis--a multi-institutional collaborative study--The Inosiplex-SSPE Research Committee","volume":"9","author":"Fukuyama","year":"1987","journal-title":"Brain Dev"},{"key":"R50-2-20240828","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(82)92097-9","article-title":"Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients","volume":"1","author":"Jones","year":"1982","journal-title":"Lancet"},{"key":"R51-2-20240828","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/159.4.748","article-title":"Oral ribavirin therapy for subacute sclerosing panencephalitis","volume":"159","author":"Ogle","year":"1989","journal-title":"J Infect Dis"},{"key":"R52-2-20240828","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.38.4.653","article-title":"Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters","volume":"38","author":"Honda","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-2-20240828","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/AAC.40.1.241","article-title":"Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis","volume":"40","author":"Ishii","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-2-20240828","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.48.12.4631-4635.2004","article-title":"Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis","volume":"48","author":"Hosoya","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R55-2-20240828","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0387-7604(03)00062-7","article-title":"Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan","volume":"25","author":"Tomoda","year":"2003","journal-title":"Brain Dev"},{"key":"R56-2-20240828","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0000000000002181","article-title":"Maintaining concentration of ribavirin in cerebrospinal fluid by a new dosage method; 3 cases of subacute sclerosing panencephalitis treated using a subcutaneous continuous infusion pump","volume":"38","author":"Miyazaki","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R57-2-20240828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/08830738030180020701","article-title":"Combined treatment with subcutaneous interferon-alpha, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis","volume":"18","author":"Aydin","year":"2003","journal-title":"J Child Neurol"},{"key":"R58-2-20240828","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7883\/yoken.JJID.2020.481","article-title":"Antiviral effect of favipiravir (T-705) against measles and subacute sclerosing panencephalitis viruses","volume":"74","author":"Hashimoto","year":"2021","journal-title":"Jpn J Infect Dis"},{"key":"R59-2-20240828","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/WNL.19.11.1080","article-title":"Amantadine therapy in subacute sclerosing panencephalitis. A preliminary report","volume":"19","author":"Haslam","year":"1969","journal-title":"Neurology"},{"key":"R60-2-20240828","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ana.410080414","article-title":"Review of 38 cases of subacute sclerosing panencephalitis: Effect of amantadine on the natural course of the disease","volume":"8","author":"Robertson","year":"1980","journal-title":"Ann Neurol"},{"key":"R61-2-20240828","first-page":"59","article-title":"Aprepitant in the treatment of subacute sclerosing panencephalitis: A randomized, double-blind, placebo-controlled study","volume":"110","author":"Oncel","year":"2020","journal-title":"PediatrNeurol"},{"key":"R62-2-20240828","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5694\/j.1326-5377.1988.tb139573.x","article-title":"Intraventricular administration of interferon and administration of methisoprinol by mouth in the treatment of adult-onset subacute sclerosing panencephalitis","volume":"148","author":"Harbord","year":"1988","journal-title":"Med J Aust"},{"key":"R63-2-20240828","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.42.3.488","article-title":"Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis","volume":"42","author":"Yalaz","year":"1992","journal-title":"Neurology"},{"key":"R64-2-20240828","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/088307380301801201","article-title":"Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): Internationalmulticenter study","volume":"18","author":"Gascon","year":"2003","journal-title":"J Child Neurol"},{"key":"R65-2-20240828","first-page":"54","article-title":"Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis","volume":"24","author":"Tomoda","year":"2001","journal-title":"PediatrNeurol"},{"key":"R66-2-20240828","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/088307380201700911","article-title":"Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex","volume":"17","author":"Solomon","year":"2002","journal-title":"J Child Neurol"},{"key":"R67-2-20240828","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-3083.1973.tb02045.x","article-title":"Immunological features in a case of subacute sclerosing panencephalitis treated with transfer factor","volume":"2","author":"Vandvik","year":"1973","journal-title":"Scand J Immunol"},{"key":"R68-2-20240828","first-page":"72","article-title":"Intravenous \u03b3-globulin treatment in a patient with subacute sclerosing panencephalitis","volume":"14","author":"Yavuz G\u00fcrer","year":"1996","journal-title":"PediatrNeurol"},{"key":"R69-2-20240828","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1176\/appi.neuropsych.12100244","article-title":"Steroid-responsive myoclonus in adult-onset subacute sclerosing panencephalitis","volume":"25","author":"Sharma","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R70-2-20240828","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ana.410140416","article-title":"Plasmapheresis does not affect subacute sclerosing panencephalitis","volume":"14","author":"Rotteveel","year":"1983","journal-title":"Ann Neurol"},{"key":"R71-2-20240828","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/dmcn.12747","article-title":"Mesenchymal stem cell application in children with subacute sclerosing panencephalitis","volume":"57","author":"Ku\u015fkonmaz","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"R72-2-20240828","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1059-1311(02)00268-6","article-title":"The use of the ketogenic diet in a patient with subacute sclerosing panencephalitis","volume":"12","author":"Bautista","year":"2003","journal-title":"Seizure"},{"key":"R73-2-20240828","first-page":"e5485","article-title":"Substantial remission in subacute sclerosing panencephalitis by following the ketogenic diet: A case report","volume":"11","author":"Nathan","year":"2019","journal-title":"Cureus"},{"key":"R74-2-20240828","doi-asserted-by":"crossref","first-page":"e000176","DOI":"10.1136\/bmjno-2021-000176","article-title":"Clinical and magnetic resonance study of a case of subacute sclerosing panencephalitis treated with ketogenic diet","volume":"3","author":"Valente","year":"2021","journal-title":"BMJ Neurol Open"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_655_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:15:30Z","timestamp":1787757330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_655_22"}},"subtitle":["An Area of Darkness"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_655_22","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}